Phase-I trial of survivin inhibition with EZN-3042 in dogs with spontaneous lymphoma

BACKGROUND: Lymphoma is a common cancer in dogs. While most dogs receiving chemotherapy experience remission, very few are cured, and median survival times are generally in the 12-month range. Novel approaches to treatment are unquestionably needed. The Inhibitor of Apoptosis Protein (IAP) family me...

Descripción completa

Detalles Bibliográficos
Autores principales: Thamm, Douglas H., Joseph, Jenette K., Rose, Barbara J., Meuten, Travis K., Weishaar, Kristen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092583/
https://www.ncbi.nlm.nih.gov/pubmed/32209084
http://dx.doi.org/10.1186/s12917-020-02317-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092583/
https://www.ncbi.nlm.nih.gov/pubmed/32209084
http://dx.doi.org/10.1186/s12917-020-02317-3

Ejemplares similares